Humulin M3

Humulin M3 is a premixed insulin suspension for injection that contains insulin human at a concentration of 100 U/mL, composed of 30 % regular insulin and 70 % NPH insulin. It is a prescription‑only product marketed in the European Union and is used to help manage blood glucose levels in people with diabetes. It provides rapid‑acting and intermediate‑acting components to cover meals and basal needs, and is administered subcutaneously under a healthcare professional’s guidance.

Humulin M3 is indicated for the treatment of diabetes mellitus when a combined rapid‑acting and intermediate‑acting insulin regimen is appropriate.

- Type 1 diabetes mellitus in adults and children requiring basal and mealtime insulin coverage. - Type 2 diabetes mellitus when oral agents no longer achieve target glycaemic control. - Adjunct therapy during periods of increased insulin demand, such as illness or pregnancy. - Transition from separate regular and NPH injections to a single premixed preparation. - Use in patients who prefer fewer daily injections while maintaining glycaemic stability.

Adverse reactions to Humulin M3 may vary in frequency and severity; they are typically categorized as common or serious.

Common: - Hypoglycaemia, presenting as sweating, tremor, hunger, or confusion. - Injection‑site reactions such as redness, swelling, or itching. - Weight gain associated with improved glycaemic control. - Lipodystrophy at the injection site with repeated use. - Transient blurred vision during rapid glucose shifts.

Serious: - Severe hypoglycaemia leading to loss of consciousness or seizures. - Allergic reactions including urticaria, angio‑edema, or anaphylaxis. - Hypersensitivity to protamine causing systemic symptoms. - Persistent hyperglycaemia indicating possible insulin resistance or dosing error.

When prescribing or using Humulin M3, clinicians and patients should consider several precautionary measures to minimise risks and optimise therapy.

- Assess renal and hepatic function, as impairment may alter insulin clearance. - Educate patients on recognising and treating hypoglycaemia promptly. - Adjust dose during periods of illness, stress, or changes in physical activity. - Avoid mixing Humulin M3 with other insulin products in the same syringe. - Monitor blood glucose regularly to detect under‑ or over‑dosing. - Consider pregnancy status; insulin requirements often change during gestation.

Humulin M3 can interact with other medicines, affecting glucose control or insulin action; awareness of these interactions helps maintain safe therapy.

Avoid: - Concurrent use of sulfonylureas or meglitinides may cause additive hypoglycaemia. - Beta‑blockers can mask typical hypoglycaemia symptoms, delaying recognition. - MAO inhibitors have no known direct effect, but close monitoring is advised.

Use with caution: - Corticosteroids may increase insulin resistance, requiring dose adjustments. - Thiazide diuretics can raise blood glucose levels, potentially reducing insulin effectiveness. - Alcohol intake can precipitate delayed hypoglycaemia, especially after bedtime dosing.